Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis

Zhou, Xiaoying; Xiao, Chuanguang; Han, Tong; Qiu, Shusheng; Wang, Meng; Chen, Jun; Sun, Weike; Li, Liang; Lin, Lili

doi:10.1186/s12957-020-02026-z

Cited by 21 publications

(12 citation statements)

References 45 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, combination immunotherapy studies have shown better response compared to monotherapies using PD-1/PD-L1 inhibitors in cancer treatment [ 36 ]. Therefore, novel biomarkers associated with response to chemotherapy and prognosis should also be investigated to enhance the chemotherapy response and improve the outcome in TNBC [ 37 – 39 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

et al. 2021

View full text Add to dashboard Cite

Background Studies on PD-L1 expression in breast cancer have gained importance in recent years, especially in triple-negative breast cancer (TNBC). Our aim was to analyze the differential expression of PD-L1 to explore its correlation with response to neoadjuvant chemotherapy (NACT) and patient survival. Methods PD-L1 expression was evaluated immunohistochemically (Ventana SP263 clone kit) by staining tumor specimen. PD-L1 positivity was defined as membranous staining > 1%, > 5%, > 10%, and > 20% on either tumor cell (TC) and /or immune cell (IC). Results Fifty patients with locally advanced TNBC, who had a partial response to NACT, were included in the study. PD-L1 staining was observed in TCs in 25 patients (50%) and in ICs in 23 patients (46%) when PD-L1 > 1% was considered positive. Patients with PD-L1 positivity on ICs were more likely to respond to chemotherapy as measured by “MD Anderson Cancer Center Residual Cancer Burden Index” (14/22, 63.6% vs. 10/27, 37%, p = 0.064). The 5-year disease-free survival (DFS) and disease-specific survival (DSS) rates were 46.3% and 51.4%, respectively. A high (> 20%) tumoral PD-L1 positivity was associated with a better DFS and DSS. Conclusions Studies in the literature mostly focused on PD-L1 expression in inflammatory cells. However, our results suggest that patients with a high PD-L1 expression on TCs were more likely to have a better outcome. Since patients with residual tumor burden who express PD-L1 on TILs were more likely to respond to NACT, an immune checkpoint inhibitor therapy in addition to NACT would be an important option for TNBC with locally advanced disease.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Therefore, novel biomarkers associated with response to chemotherapy and prognosis should also be investigated to enhance the chemotherapy response and improve the outcome in TNBC [37][38][39].…”

Section: Discussionmentioning

confidence: 99%

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Hence, MRPL13 could indicate the poor prognosis of breast cancer. 11 However, the role of MRPL13 in NSCLC has not been described yet.…”

Section: Introductionmentioning

confidence: 99%

MRPL13 Act as a Novel Therapeutic Target and Could Promote Cell Proliferation in Non-Small Cell Lung Cancer

Jing¹,

Fu²,

Wang³

et al. 2021

CMAR

View full text Add to dashboard Cite

Background:The latent involvement of MRPL13 in non-small cell lung cancer (NSCLC) remains unclear. This study aimed to explore the role of MRPL13 in NSCLC. Methods: All analyses were performed in R software 4.0, SPSS version 23, and GraphPad Prism 8. The "limma" package was used to identify differentially expressed genes. Univariate and multivariate cox analyses were used to identify prognosis-related genes. A549 and H1299 lung cancer cell lines were selected for phenotypic experiments.Results: The high level of MRPL13 was correlated with poor T classification and overall survival. In vitro experiments showed that MRPL13 was highly expressed in NSCLC tissue and cell lines. MRPL13 knockdown inhibited the proliferation of lung cancer A549 and H1299 cell lines, which was further validated by in vivo experiment. Moreover, GSEA analysis suggested that the pathway of MYC target, PI3K/AKT/mTOR/ signaling, oxidative phosphorylation, and G2/M checkpoints may be the potential pathway where MRPL13 was involved. Meanwhile, MRPL13 demonstrated a negative correlation with M1 macrophage, CD8+ T cells, and CD4+ T cells, making it an underlying immunotherapy target of NSCLC. Conclusion: MRPL13 may promote the proliferation of NSCLC cells and serve as an independent tumor marker and an emerging therapeutic target.

show abstract

“…Tumorigenesis is often associated with alterations in the stromal environment and immune status, mainly manifested as changes in the tumor microenvironment (TME) [ 14 , 15 ]. TME plays a key role in several steps of tumor development, including local drug resistance, immune escape, recurrence, and distant metastasis [ 16 , 17 ]. Tumor cell exposure to TME also contributes to shaping the tissue-specificity of driver genes [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Comprehensive analysis of the cancer driver genes in breast cancer demonstrates their roles in cancer prognosis and tumor microenvironment

Gao

Liu

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

Background Breast cancer is the most common malignancy in women. Cancer driver gene-mediated alterations in the tumor microenvironment are critical factors affecting the biological behavior of breast cancer. The purpose of this study was to identify the expression characteristics and prognostic value of cancer driver genes in breast cancer. Methods The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets are used as the training and test sets. Classified according to cancer and paracancerous tissues, we identified differentially expressed cancer driver genes. We further screened prognosis-associated genes, and candidate genes were submitted for the construction of a risk signature. Functional enrichment analysis and transcriptional regulatory networks were performed to search for possible mechanisms by which cancer driver genes affect breast cancer prognosis. Results We identified more than 200 differentially expressed driver genes and 27 prognosis-related genes. High-risk group patients had a lower survival rate compared to the low-risk group (P<0.05), and risk signature showed high specificity and sensitivity in predicting the patient prognosis (AUC 0.790). Multivariate regression analysis suggested that risk scores can independently predict patient prognosis. Further, we found differences in PD-1 expression, immune score, and stromal score among different risk groups. Conclusion Our study confirms the critical prognosis role of cancer driver genes in breast cancer. The cancer driver gene risk signature may provide a novel biomarker for clinical treatment strategy and survival prediction of breast cancer.

show abstract

Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis

Cited by 21 publications

References 45 publications

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

MRPL13 Act as a Novel Therapeutic Target and Could Promote Cell Proliferation in Non-Small Cell Lung Cancer

Comprehensive analysis of the cancer driver genes in breast cancer demonstrates their roles in cancer prognosis and tumor microenvironment

Contact Info

Product

Resources

About